Moreover, UC–CRC cases presented much higher methylation levels of RUNX3 than UC controls, indicating that RUNX3 agonists might play an anti-inflammatory and anti-cancer role in clinical settings (Garrity-Park et al., 2010). Here, RUNX3 is linked to colorectal carcinoma.